editor@jprims.in
9343055451
e-ISSN: 3049-1681
logo

Journal of Pharmaceutical Research and Integrated Medical Sciences

📢 Latest Update: New special issue call for papers on "Pharmaceutical Research and Integrated Medical Sciences" - Submit by March 31, 2026

📢 Latest Update: New special issue call for papers on "Pharmaceutical Research and Integrated Medical Sciences" - Submit by March 31, 2026

Volume 3, Issue 6 - 2026 (JPRIMS, Vol-3, Issue-06, June-2026)

Volume 3 Issue 6 Cover

Issue Details:

Volume 3 Issue 6
Published:Invalid Date

Editorial: JPRIMS, Vol-3, Issue-06, June-2026

Welcome to the 2026 issue of Journal of Pharmaceutical Research and Integrated Medical Sciences. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr. Arpan Kumar Tripathi
Editor-in-Chief
Journal of Pharmaceutical Research and Integrated Medical Sciences

Articles in This Issue

Showing 9 of 9 articles
Research PaperID: jprims-00000266

Eye spasm/Eye twitching: Mg Supplementation and Stress-Reduction in Treating Eyelid Myokymia, Psychosomatic of Anxiety:  of Eye Twitching Among High-Stress, Hemifacial Spasm,Blepharospasm

Yash Srivastav Srivastav, Stuti Verma Verma, Raman Srivastava Srivastava, Tanya Tanya, Shivani Singh Singh, Anup Kumar Sirbaiya Sirbaiya, Deepshi Srivastava Srivastava

Eyelid twitching and involuntary facial muscle spasms have become common neuromuscular disorders due to stress, anxiety, sleeplessness, prolonged computer usage, exhaustion, and other external factors. The purpose of this review is to discuss various neurophysiological, psychosomatic, environmental, and medical aspects of eye twitching disorders such as eyelid myokymia, hemifacial spasm, and blepharospasm in highly stressed people. Human research demonstrates that chronic stress along with dysfunction in the autonomic nervous system plays an important role in neuromuscular hyperactivity and ocular muscle spasms. Magnesium is discussed in this review as an important nutrient for nerve signaling, muscle relaxation, and neurotransmitter function. Therefore, magnesium intake in combination with stress management methods like meditation, yoga, and sleep may help alleviate the symptoms of eyelid twitches. Neurological complications like hemifacial spasm and blepharospasm generally require the intervention of drugs, neurological procedures like botulinum toxin injection therapy, anticonvulsants, and microvascular decompression surgery. The review also touches upon the effects of prolonged muscular spasm within the eye muscles on emotions, occupation, and quality of life from a psychosocial perspective. While previous human-based studies have shed light on various clinical aspects of the subject, there remain certain issues like small sample size, variation in therapeutic protocols, and absence of longitudinal studies that underscore the need for further clinical research.

Nuclear ReprogrammingEpigenetic ReprogrammingHuman Clone DevelopmentGenomic ReplicationSomatic Cell Nuclear Transfer
17,690 views
5,296 downloads

Contributors:

 Yash Srivastav Srivastav
,
 Stuti Verma Verma
,
 Raman Srivastava Srivastava
,
 Tanya Tanya
,
 Shivani Singh Singh
,
 Anup Kumar Sirbaiya Sirbaiya
,
 Deepshi Srivastava Srivastava
Research PaperID: jprims-00000267

Large Language Models (LLMs) in Hypnosis, Leveraging Machine Learning to Map and Induce Hypnotic Trance States via Real-Time EEG, DORAs, VRH, HRV: Human-Led Hypnosis vs Algorithmically Hypnotherapy for Pain Management

Yash Srivastav Srivastav, Raman Srivastava Srivastava, Stuti Verma Verma, Anup Kumar Sirbaiya Sirbaiya, Shivani Singh Singh, Kamini Prajapati Prajapati, Vasu Tiwari Tiwari

The investigation assessed the potential applications of LLMs, EEG neurofeedback, HRV analysis, DORAS systems, and VRH in the development of AI-powered hypnotherapy solutions for pain therapy. The results proved that AI-based hypnotherapy platforms had higher levels of customization, ability to monitor the states of trance, maintain consistency of sessions, and promote physiological adaptations compared to conventional hypnotherapy approaches based on human hypnotherapists. The quantitative analysis revealed that hypnotherapy sessions assisted by VRH delivered the most effective pain relief outcomes, whereas the EEG and HRV assessments revealed enhanced levels of autonomic relaxation and emotional control in the context of hypnotherapy. The researchers found that despite obvious strengths in terms of scalability, incorporation of neurofeedback, and responsiveness to individual conditions of patients, AI systems lack some qualities inherent to humans such as emotional empathy and rapport building. Overall, it can be concluded that future hypnotherapy systems are more likely to become hybrid human-AI solutions.

Psychosomatic StressNeuromuscular DisordersBlepharospasmHemifacial SpasmStress and AnxietyMagnesium Supplementation+2 more
17,532 views
5,394 downloads

Contributors:

 Yash Srivastav Srivastav
,
 Raman Srivastava Srivastava
,
 Stuti Verma Verma
,
 Anup Kumar Sirbaiya Sirbaiya
,
 Shivani Singh Singh
,
 Kamini Prajapati Prajapati
,
 Vasu Tiwari Tiwari
Research PaperID: jprims-00000268

Modulating The Epigenetic Clock, Senolytic Therapies for Human Longevity: Age Tissue Regeneration, Synergistic Effect of Nad+ Precursors and Telomerase, Human Age Enhancement

Yash Srivastav Srivastav, Stuti Verma Verma, Anup Kumar Sirbaiya Sirbaiya, Shivani Singh Singh, Amita Singh Singh, Deepshi Srivastava Srivastava, Kamini Prajapati Prajapati

The human aging process can be characterized by progressive cellular degeneration, mitochondria malfunctioning, inflammatory responses, epigenetics modifications, and loss of tissue regenerative ability. The recent progress made in the field of longevity has revealed several promising treatment opportunities for prolonging a healthy lifespan in humans through epigenetics regulation, senolytics application, NAD+ precursors' intake, telomerase activation, and regenerative treatments. This review considers evidence from human studies about the impact of DNA methylation, cell senescence elimination, mitochondria recovery, enhanced immunity, tissue renewal, and cognitive reserve increase in human aging biology. According to findings based on human research, interventions involving senolytic compounds, Nicotinamide Riboside (NR), Nicotinamide Mononucleotide (NMN), and telomerase-linked regenerative treatment have the ability to contribute to improved metabolism, vascular functions, immunological resilience, and cognitive efficiency while reducing inflammatory processes and decreasing the number of senescent cells in a human body. In addition, comprehensive longevity approaches consisting of the mentioned interventions seem to possess combined benefits in terms of human longevity improvement. However, there are certain drawbacks that must be addressed when applying these interventions into clinical practice; namely, small sample sizes used in studies, lack of long-term safety testing, ethical issues, and inadequate biomarkers. Future directions in the research are discussed.

Digital TherapeuticsVRHAI HypnotherapyNeurofeedbackPain ManagementMachine Learning+4 more
17,624 views
5,414 downloads

Contributors:

 Yash Srivastav Srivastav
,
 Stuti Verma Verma
,
 Anup Kumar Sirbaiya Sirbaiya
,
 Shivani Singh Singh
,
 Amita Singh Singh
,
 Deepshi Srivastava Srivastava
,
 Kamini Prajapati Prajapati
Research PaperID: jprims-00000269

Nano Delivery of Flavonoids in NSCLC: Mechanistic Insights and Translational Perspectives

Pavani Sure Sure, N. Sandeepthi Sandeepthi, Bodige Mounika Mounika, Thaneru Kruthika Kruthika, M. Srinivasa Murthy Murthy

Non-small cell lung cancer (NSCLC) has high mortality rates owing to multidrug resistance, inadequate tumor selectivity, and systemic toxicity associated with conventional chemotherapy. In contrast, flavonoids, including fisetin, quercetin, and flavokavain A, show promising anticancer activity. However, their clinical application is limited by poor solubility, instability, and insufficient intracellular accumulation. Recent studies, mainly on nanostructured lipid carriers (NLCs), have provided a strategic approach to address these challenges. This critical review examines nanocarrier-enabled flavonoid delivery systems for NSCLC, focusing on the role of lipid-based nanocarriers in enhancing pharmacokinetics, improving tumor targeting, and reversing drug resistance mechanisms. Surface-functionalized NLCs, including hyaluronic acid (HA) and protein-based ligands, facilitate receptor-mediated uptake, enhance therapeutic efficacy, and inspire current preclinical evidence. This review discusses the mechanistic advantages and translational potential of NLC-based flavonoid delivery and identifies the important challenges that must be addressed for clinical advancement.

Healthy AgingMitochondrial RejuvenationTissue RegenerationTelomerase ActivationNAD+ PrecursorsHuman Longevity+2 more
17,709 views
5,322 downloads

Contributors:

 Pavani Sure Sure
,
 N. Sandeepthi Sandeepthi
,
 Bodige Mounika Mounika
,
 Thaneru Kruthika Kruthika
,
 M. Srinivasa Murthy Murthy
Research PaperID: jprims-00000270

Mpox Virus Variants Clade-I and Clade-II Pathogenesis: Mapping the Genetic Mutations, Impact on Viral Fitness, Efficiency of Human-To-Human Transmission, Epidemiological Surveillance

Yash Srivastav Srivastav, Stuti Verma Verma, Shivani Singh Singh, Vivek Kumar Kumar, Kamini Prajapati Prajapati, Anup Kumar Sirbaiya Sirbaiya, Saroj Kumar Kumar

The mpox virus (MPXV), which is an emergent orthopoxvirus with zoonotic transmission capability, represents a growing public health threat on a global scale due to the recently reported outbreaks in multiple countries after 2022. In view of the rising prevalence of genetically heterogeneous strains, such as Clade I and Clade II, there has been a growing research focus on the molecular aspects of pathogenesis, evolution, transmission, and epidemiology of MPXV clades. The current review focuses on the genome structure, mutations, viral fitness, immune evasiveness, and human-to-human transmission rate associated with MPXV clades. The comparative pathogenicity between the Clade I and Clade II variants is also discussed, with emphasis on the increased virulence and mortality related to Clade I and increased transmissibility of Clade II variants, including Clade IIb. Recent genomic studies have shown that hypermutations caused by the APOBEC3 enzymes, single-nucleotide polymorphism, and adaptive evolution contribute to viral persistence, immune escape, and epidemic spread. Furthermore, the review explains how epidemiologic surveillance efforts, molecular diagnostic tools, genomics techniques, and public health issues related to mpox epidemic response are managed. This information highlights the crucial role of genomics surveillance, timely diagnostics, vaccines, and the One Health approach in future prevention of mpox outbreaks.

Nanostructured lipid carriersFlavonoidsNSCLCTargeted nanomedicineMultidrug resistanceLipid-based nanocarrier
17,759 views
5,352 downloads

Contributors:

 Yash Srivastav Srivastav
,
 Stuti Verma Verma
,
 Shivani Singh Singh
,
 Vivek Kumar Kumar
,
 Kamini Prajapati Prajapati
,
 Anup Kumar Sirbaiya Sirbaiya
,
 Saroj Kumar Kumar
Research PaperID: jprims-00000271

Improving Oral Bioavailability of Poorly Water-Soluble Drugs: Recent Progress in Solid Dispersions, Lipid Systems, and Nanotechnology

Khemraj Dewangan Dewangan, Satyanand Vishal Vishal, Anurima chauhan chauhan, Shreya Kashyap Kashyap, Virendra Kumar Pradhan Pradhan

Poor aqueous solubility remains one of the most significant challenges in pharmaceutical development, affecting approximately 40% of marketed drugs and 70–90% of developmental candidates. This constraint translates directly into inadequate oral bioavailability, reduced therapeutic efficacy, high inter- and intra-subject variability, and compromised dose proportionality. The Biopharmaceutical Classification System (BCS) characterises drugs with low solubility and high permeability (Class II) and those with both low solubility and permeability (Class IV) as particularly problematic for conventional oral formulation. Over the past two decades, three primary technological paradigms have emerged to address this challenge: solid dispersions, lipid-based formulations, and nanotechnology-enabled delivery systems. This review synthesises recent advances (2022–2025) across these platforms, examining their mechanistic basis, formulation strategies, in vivo performance, and regulatory landscape. We demonstrate that hybrid approaches combining multiple technologies now routinely achieve 3–7-fold improvements in oral bioavailability and are increasingly entering clinical practice

epidemiologyOne Healthpathogenesisgenomic surveillancehuman-to-human transmissionviral fitness+4 more
18,235 views
5,411 downloads

Contributors:

 Khemraj Dewangan Dewangan
,
 Satyanand Vishal Vishal
,
 Anurima chauhan chauhan
,
 Shreya Kashyap Kashyap
,
 Virendra Kumar Pradhan Pradhan
Research PaperID: jprims-00000272

Real-World Efficacy and Safety Profile of Atezolizumab in Indian Patients With PD-L1-Positive Advanced Malignancies: Evaluating the Therapeutic Efficacy of Overexpressing, Re-Engineering the Host Immune Response Against Cancer

Yash Srivastav Srivastav, Shivani Singh Singh, Stuti Verma Verma, Kamini Prajapati Prajapati, Vivek Kumar Kumar, Anup Kumar Sirbaiya Sirbaiya, Amita Singh Singh

Immunotherapy for cancer treatment has proved to be a very useful technique that helps to boost the immune responses of the host against cancer cells. In this study, the effectiveness of atezolizumab is assessed in Programmed Death-Ligand 1(PD-L1) Positive advanced cancers of Indians. This study was performed using a retrospective analysis on the clinical data of 120 patients that received atezolizumab treatment between 2021 and 2025. Patients with advanced solid malignancies such as non-small cell lung carcinoma (NSCLC), hepaticellular carcinoma (HCC), and triple-negative breast cancer (TNBC) were included in this study. The RECIST 1.1 criteria and CTCAE Version 5.0 recommendations were used to assess the response to therapy, progression-free survival, overall survival, and adverse events linked to the immune system, respectively. Kaplan-Meier survival analysis, chi-square testing, and descriptive statistics were all part of the statistical package. The results demonstrated that patients exhibiting elevated levels of PD-L1 had a substantially better chance of surviving. In total, 76.6% of people were able to keep the sickness at bay, whereas only 48.3% responded. Treatment response is strongly correlated with PD-L1 over-expression (χ² = 9.64, p = 0.002). Adverse reactions experienced by subjects in this study were mostly mild-to-moderate. It was concluded in this study that atezolizumab is an effective and safe immunotherapy drug for treating PD-L1-positive malignancies in Indians.

Lipidproblematicsolid dispersionswaterdrug development
18,424 views
5,471 downloads

Contributors:

 Yash Srivastav Srivastav
,
 Shivani Singh Singh
,
 Stuti Verma Verma
,
 Kamini Prajapati Prajapati
,
 Vivek Kumar Kumar
,
 Anup Kumar Sirbaiya Sirbaiya
,
 Amita Singh Singh
Research PaperID: jprims-00000273

Bridging Food Packaging and Biomedical Applications Using Stimuli-Responsive Natural Polymer–Nanoclay Composites

B Sabana Sabana, Umamaheswari R R, Bhuvaneswari.G G, Mumtaz Begum Begum, Deepikaa R R

The growing demand for sustainable, high-performance materials has accelerated research into natural polymer–nanoclay composites as alternatives to petroleum-based plastics and conventional biomaterials. Natural polymers such as cellulose, chitosan, and alginate offer biodegradability, biocompatibility, and chemical functionality, but their standalone use is often limited by inadequate mechanical strength, thermal stability, and barrier performance. Incorporation of naturally occurring nanoclays, including montmorillonite and halloysite nanotubes, overcomes these limitations by providing structural reinforcement, enhanced barrier properties, and tunable bioactive delivery capabilities. This review critically examines recent advances in the design, interfacial chemistry, and multifunctional performance of natural polymer–nanoclay composites, with particular emphasis on stimuli-responsive behavior and bioactive loading strategies. Mechanisms governing pH-, temperature-, moisture-, ionic-, and light-responsive responses are discussed in relation to controlled release and adaptive functionality. A comparative perspective highlights how shared material principles are tailored to meet the distinct performance and regulatory requirements of food packaging and biomedical applications, including shelf-life extension, antimicrobial activity, wound healing, and drug delivery. Fabrication approaches, scale-up challenges, and safety and regulatory considerations relevant to both sectors are also addressed. Despite substantial progress, challenges remain in achieving scalable manufacturing, ensuring long-term safety, and minimizing environmental persistence of nanoclay components. Overall, natural polymer–nanoclay composites represent a promising class of multifunctional, sustainable materials capable of bridging food safety and biomedical innovation through rational material design.

AtezolizumabPD-L1ImmunotherapyAdvanced MalignanciesNon-Small Cell Lung CarcinomaTriple-Negative Breast Cancer+4 more
18,551 views
5,438 downloads

Contributors:

 B Sabana Sabana
,
 Umamaheswari R R
,
 Bhuvaneswari.G G
,
 Mumtaz Begum Begum
,
 Deepikaa R R
Research PaperID: jprims-00000274

Overcoming Barriers in HAND Treatment: Challenges and Future Prospects of Polymeric Nano formulations

Yatindra Kumar Kumar, Mudit Kumar Kumar, Sachin Kumar Kumar, Meenakshi Verma Verma, Amita Tilak Tilak

Context: One of the most prevalent comorbidities in the ART era is Human immunodeficiency virus-related neurocognitive disorder. The prevalence of HIV-Associated Neurocognitive Disorder is said to vary from 20% to 88%. A promising approach to treating and preventing neurocognitive problems in Human immunodeficiency virus-positive individuals is the encapsulation of nanosized antiretrovirals in various polymers, which can improve their absorption into the central nervous system and other latent viral reservoirs.Primary text: The term HAND refers to the range of neurocognitive impairments associated with Human immunodeficiency virus infection. Declining brain activity leads to neurocognitive issues.Although ART has been utilised to improve cognitive function and reverse the course of the disease, hand diseases presently lack a distinct form of therapy. Adsorbed onto or incorporated into a polymer matrix, polymeric nanoformulations are solid colloidal systems containing active therapeutic ingredients. Particle sizes for these substances range from 1 to 1,000 nm. An array of hydrophilic and hydrophobic medications, vaccines, peptides, and biological macromolecules may be delivered in a controlled manner using polymeric nanoformulations. Conclusion: When PNPs are actively targeted, promising outcomes have been shown in preclinical research and, in certain situations, early clinical trials. Since polymeric nanoformulations have the potential to eliminate latent viral reservoirs, more Study is needed on their use in HAND treatment. Furthermore, new antiviral drugs that are safe, effective, and simple to use for both adult and pediatric HIV+ patients are required.

Natural PolymersNanoclaysStimuli-Responsive CompositesBioactive DeliveryFood PackagingBiomedical Applications
18,310 views
5,536 downloads

Contributors:

 Yatindra Kumar Kumar
,
 Mudit Kumar Kumar
,
 Sachin Kumar Kumar
,
 Meenakshi Verma Verma
,
 Amita Tilak Tilak